4.78
price up icon0.74%   0.035
after-market Handel nachbörslich: 4.65 -0.13 -2.72%
loading
Schlusskurs vom Vortag:
$4.745
Offen:
$4.67
24-Stunden-Volumen:
2.82M
Relative Volume:
1.16
Marktkapitalisierung:
$368.13M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.9146
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
-14.49%
1M Leistung:
-28.12%
6M Leistung:
-23.76%
1J Leistung:
-48.90%
1-Tages-Spanne:
Value
$4.65
$4.955
1-Wochen-Bereich:
Value
$4.65
$5.63
52-Wochen-Spanne:
Value
$4.65
$11.16

Altimmune Inc Stock (ALT) Company Profile

Name
Firmenname
Altimmune Inc
Name
Telefon
(240) 654-1450
Name
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
Mitarbeiter
59
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
ALT's Discussions on Twitter

Vergleichen Sie ALT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALT
Altimmune Inc
4.78 368.13M 409.00K -101.35M -71.49M -1.64
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-28 Eingeleitet William Blair Mkt Perform
2025-01-08 Eingeleitet Stifel Buy
2024-11-12 Eingeleitet UBS Buy
2024-04-29 Herabstufung Guggenheim Buy → Neutral
2024-01-24 Eingeleitet Goldman Neutral
2023-03-22 Herabstufung Goldman Buy → Neutral
2022-12-01 Eingeleitet Goldman Buy
2021-12-29 Fortgesetzt Jefferies Buy
2021-06-02 Eingeleitet H.C. Wainwright Buy
2021-02-11 Eingeleitet Guggenheim Buy
2020-12-14 Eingeleitet Jefferies Buy
2020-11-12 Bestätigt B. Riley Securities Buy
2020-09-25 Eingeleitet B. Riley FBR Buy
2020-08-14 Eingeleitet Evercore ISI Outperform
2020-07-31 Eingeleitet Piper Sandler Overweight
2020-07-28 Eingeleitet JMP Securities Mkt Outperform
2020-02-24 Fortgesetzt ROTH Capital Buy
2019-07-19 Eingeleitet ROTH Capital Buy
2017-10-09 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Altimmune Inc Aktie (ALT) Neueste Nachrichten

pulisher
Apr 01, 2025

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon - MSN

Apr 01, 2025
pulisher
Mar 31, 2025

PharmAthene stock hits 52-week low at $5.1 amid challenges By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

PharmAthene stock hits 52-week low at $5.1 amid challenges - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Mar 31, 2025
pulisher
Mar 22, 2025

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - Yahoo

Mar 22, 2025
pulisher
Mar 19, 2025

Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey

Mar 19, 2025
pulisher
Mar 17, 2025

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine (ALT) - Seeking Alpha

Mar 17, 2025
pulisher
Mar 17, 2025

Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Mar 17, 2025
pulisher
Mar 17, 2025

Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 16, 2025

Altimmune rises as buyout rumors follow R&D updates - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Altimmune CFO Gregory Weaver purchases $51,996 in stock By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Altimmune Outlines Pemvidutide Plans In MASH And Beyond - insights.citeline.com

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune soars amid takeover speculation - MSN

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune stock rises amid buyout and R&D news(ALT:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

(ALT) Trading Advice - Stock Traders Daily

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Stifel maintains Buy on Altimmune stock, $18 price target - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Stifel maintains Buy on Altimmune stock, $18 price target By Investing.com - Investing.com UK

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune rises on plans to test obesity drug for alcohol use disorder, other conditions - TradingView

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune CFO Gregory Weaver purchases $51,996 in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens JMP reiterates Altimmune stock with $25 target By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens JMP reiterates Altimmune stock with $25 target - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Promising Potential of Altimmune’s Pemvidutide Drives Buy Rating Amid Expanding Indications and Strong Market Outlook - TipRanks

Mar 14, 2025
pulisher
Mar 13, 2025

Altimmune to test obesity drug for alcohol use disorder and related health conditions - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Unpartnered Obesity Assets Are Becoming Slim Pickings For Pharma - insights.citeline.com

Mar 13, 2025
pulisher
Mar 12, 2025

SBI Securities Co. Ltd. Acquires New Shares in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Mar 12, 2025
pulisher
Mar 10, 2025

Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 09, 2025

Altimmune, Inc. to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 07, 2025

Rhumbline Advisers Has $756,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

HC Wainwright Has Bearish Estimate for Altimmune Q2 Earnings - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Altimmune to Host Virtual R&D Day on March 13, 2025 - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Can Altimmune's Pemvidutide Transform Both Obesity and MASH Treatment? R&D Day to Reveal Full Potential - StockTitan

Mar 06, 2025
pulisher
Mar 06, 2025

Altimmune FY2029 EPS Forecast Decreased by HC Wainwright - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire

Mar 05, 2025
pulisher
Mar 05, 2025

Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire

Mar 05, 2025

Finanzdaten der Altimmune Inc-Aktie (ALT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Kapitalisierung:     |  Volumen (24h):